Investors Expect Biopharma Volatility And Not As Much Upside in 2014
Executive Summary
Last year was the best showing for biopharma stocks since the genomics bubble in the late 1990s. Investors see valuations as stretched with only a few high-profile milestones coming up. But they still expect to see some sector performance, although not as much as last year.